Quest Diagnostics to Acquire Select Assets from Fresenius Medical Care to Enhance Dialysis Services in the U.S.

Quest Diagnostics to Acquire Select Assets from Fresenius Medical Care to Enhance Dialysis Services in the U.S.

(IN BRIEF) Quest Diagnostics has agreed to acquire select assets from Fresenius Medical Care’s Spectra Laboratories, expanding its portfolio with dialysis-related laboratory and water testing services. This collaboration will enhance the care and efficiency of dialysis services across the U.S., with Quest’s clinical expertise and national scale improving service delivery for Fresenius Medical Care’s patients.

(PRESS RELEASE) BAD HOMBURG/ SACAUCUS, NJ, United States, 24-Feb-2025 — /EuropaWire/ — Fresenius Medical Care (FME), the world leader in products and services for individuals with renal disease, and Quest Diagnostics (DGX), a major provider of diagnostic information services, have announced a strategic collaboration to enhance dialysis services in the U.S. Under the terms of a definitive acquisition agreement, Quest will acquire select assets from Fresenius Medical Care’s Spectra Laboratories, a key player in renal-specific laboratory testing.

This partnership also includes a separate agreement, under which Quest will provide comprehensive laboratory services focused on end-stage kidney disease (ESKD), as well as specialized water testing for dialysis patients and providers served by Fresenius Medical Care’s dialysis centers in the U.S. The deal is set to strengthen both companies’ capabilities in kidney disease care, allowing Fresenius to increase operational efficiencies while benefiting from Quest’s leadership in diagnostics.

Expansion of Quest’s Dialysis Testing Capabilities

Through this acquisition, Quest will gain a new dimension to its laboratory services by adding dialysis-related water testing, broadening its comprehensive testing offerings. This collaboration will enable Fresenius Medical Care to optimize its operational processes, enhancing the care for dialysis patients across the U.S. The integration of Quest’s diagnostic expertise in chronic kidney disease and transplantation services into Fresenius Medical Care’s dialysis operations is expected to create significant efficiencies for patients and providers alike.

Quest’s widespread network of laboratories will also bring testing services closer to Fresenius Medical Care’s dialysis clinics, reducing transportation times and improving the speed of result reporting, especially for some routine tests. Quest intends to utilize its laboratory network during off-peak daytime hours to ensure optimal use of its resources.

Operational and Strategic Benefits

Fresenius Medical Care’s CEO, Helen Giza, explained, “This transaction aligns with our portfolio optimization strategy to drive efficiencies and improve the experience for patients and staff. By integrating Quest’s industry-leading expertise in laboratory services into our dialysis centers, we can focus on delivering world-class dialysis care every day. Quest’s values align closely with ours, and we are confident in their ability to maintain the high standards our patients, partners, and clinical staff expect.”

Quest Diagnostics’ Chairman and CEO, Jim Davis, commented, “Our expanded relationship with Fresenius Medical Care will allow us to enhance our portfolio in chronic kidney disease care and dialysis testing. With Quest’s national scale, we can offer high-quality lab services that are more accessible to Fresenius Medical Care’s dialysis clinics and patients across the U.S.”

Financials and Timeline

The financial terms of the agreement were not disclosed. The transaction is expected to be completed by the second half of 2025, pending regulatory approval, with the full integration of services anticipated by early 2026.

Supporting Fresenius Medical Care’s Turnaround Strategy

Fresenius Medical Care has been executing a strategic transformation plan aimed at refocusing on its core strengths and maximizing profitable growth. This acquisition complements the company’s ongoing efforts to streamline its portfolio and divest non-core assets, further solidifying its position as a leader in kidney care.

Chronic Kidney Disease in the U.S.

Chronic kidney disease (CKD) affects approximately 35.5 million people in the U.S., making it one of the country’s most prevalent chronic diseases. Unfortunately, a large portion of CKD cases go undiagnosed. Once the disease progresses to end-stage kidney disease (ESKD), patients typically require dialysis or a transplant. Currently, over 800,000 people in the U.S. undergo dialysis, which necessitates regular laboratory testing and water quality assessments to ensure the safety and effectiveness of treatment.

About Fresenius Medical Care:
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,732 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 308,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

About Quest Diagnostics:
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world’s largest databases of de-identifiable clinical lab results, Quest’s diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world.
www.QuestDiagnostics.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

FME Media contact

Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com

FME Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
www.freseniusmedicalcare.com

Quest Media contact
Jen Petrella
T +1 973-520-2800
mediacontact@QuestDiagnostics.com

Quest Contact for analysts and investors
Shawn Bevec
T +1 973-520-2900
shawn.c.bevec@questdiagnostics.com
www.questdiagnostics.com

SOURCE: Fresenius Medical Care AG